ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 362

Management Of Hyperlipidemia In Patients With RA: Results From The Corrona Certain Study

Dimitrios A. Pappas1, Ani John2, Joel M. Kremer3, George W. Reed4, Tanya Sommers4, Jeffrey D. Greenberg5, Ashwini Shewade2 and Jeffrey R. Curtis6, 1Columbia University, New York, NY, 2Genentech Inc., South San Francisco, CA, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 4CORRONA, Inc., Southborough, MA, 5NYU Hospital for Joint Diseases, New York, NY, 67University of Alabama at Birmingham Division of Clinical Immunology and Rheumatology, Birmingham, AL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords:

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:  RA is associated with an increased risk for cardiovascular disease (CVD).1 Patients (pts) with RA share similar risk for CVD with non-RA pts who are 10 years older and with diabetics and may benefit from lipid-lowering therapies such as statins2; however, information on management of hyperlipidemia in pts with RA is not well characterized. This study evaluated adequacy of lipid-lowering therapy in a cohort of 779 ptswith RA participating in the CORRONA registry.

Methods:  Pts with at least moderate disease activity (CDAI > 10) initiating a biologic DMARD participated in an ongoing comparative effectiveness study (CERTAIN) nested within CORRONA. Lipid levels and information about statin or other lipid-lowering use was obtained at baseline. Clinical and demographic characteristics of pts receiving antihyperlipidemic therapy at baseline were compared with pts with increased lipid levels (LDL ≥ 100 mg/dL and LDL ≥ 130 mg/dL) who were not receiving lipid-lowering agents.

Results:  A total of 779 CERTAIN enrollments were evaluated between November 20, 2010, and July 2, 2012. At baseline, 485 (62.3%) pts had LDL ≥ 100 mg/dL (223 [28.6%] with LDL ≥ 130 mg/dL), 84 (10.8%) had HDL < 40 mg/dL, 311 (39.9%) had TC ≥ 200 mg/dL, 298 (38.3%) had TG ≥ 150 mg/dL and 69 (8.9%) had a TC/HDL ratio > 5. Of 779 pts, 191 (24.5%) were already using statins and/or other lipid-lowering therapies at baseline. A total of 408 (52.4%) pts with an LDL ≥ 100  mg/dL and 192 (24.6%) pts with LDL ≥ 130 mg/dL were not on statin therapy. Pts receiving statins were older (62.1 ± 11.0 vs 54.1 ± 12.8 years), less frequently female (66.5% vs 78.4%) and had more frequent history of CVD  (22.5 vs 3.4%) and diabetes mellitus (9.4 vs1.7%) compared with pts having LDL ≥ 100 mg/dL who were not receiving statins. Similar differences were seen comparing pts on statins with pts with LDL ≥ 130 but not on statins.

Conclusion:   Consistent with previous reports,3,4 a considerable proportion of hyperlipidemic RA pts at risk for CVD were not receiving lipid-lowering therapy. Practicing rheumatologists need to be aware of the prevalence of hyperlipidemia and appropriate management to reduce risk for CVD.

References

1.)   Gkaliagkousi E, et al. J Clin Rheumatol. 2012;18:422-30.

2.)   Sheng X, et al. J Rheumatol. 2012;39:32-40.

3.)   Toms TE, et al. Ann Rheum Dis. 2010;69:683-8.

4.)   Veetil BM, et al. J Rheumatol. 2013 May 1; [Epub ahead of print].

Disclosure:

D. A. Pappas,

CORONA ,

3,

Novartis ,

5;

A. John,

Genentech, Inc.,

3;

J. M. Kremer,

CORRONA ,

1,

CORRONA ,

3;

G. W. Reed,

CORRONA ,

3;

T. Sommers,

CORRONA ,

3;

J. D. Greenberg,

CORRONA ,

1,

AstraZeneca, CORRONA, Novartis, Pfizer,

5;

A. Shewade,

Genentech, Inc.,

3;

J. R. Curtis,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, Abb Vie,

2,

Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, Abb Vie,

5.

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-hyperlipidemia-in-patients-with-ra-results-from-the-corrona-certain-study/